Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab add-on to statins in Chinese patients with hypercholesterolemia
CTR20171443Phase 3Terminated
- Sponsor
- Amgen Astellas BioPharma
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in hypercholesterolemia, combined dyslipidaemia, sponsored by Amgen Astellas BioPharma. Started May 2019; status: terminated.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20171443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171443.